{
    "clinical_study": {
        "@rank": "67059", 
        "arm_group": [
            {
                "arm_group_label": "ALN-TTRSC", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, pharmacokinetics and\n      pharmacodynamics of ALN-TTRSC in healthy volunteer subjects."
        }, 
        "brief_title": "A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "TTR-mediated Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index (BMI) must be \u2265 16.5 kg/m2 and \u2264 35.0 kg/m2;\n\n          -  Female subjects must be of non-childbearing potential; e.g., postmenopausal or\n             pre-menopausal with surgical sterilization;\n\n          -  Male subjects agree to use appropriate contraception;\n\n          -  Adequate blood counts, liver and renal function;\n\n          -  Non-smokers for at least 3 months;\n\n          -  Willing to give written informed consent and are willing to comply with the study\n             requirements.\n\n        Exclusion Criteria:\n\n          -  Known human immunodeficiency virus (HIV) positive status or known or suspected\n             systemic bacterial, viral, parasitic, or fungal infection;\n\n          -  Subjects with a history of multiple drug allergies or intolerance to SC injection;\n\n          -  History of drug abuse and/or alcohol abuse;\n\n          -  Receiving an investigational agent within 3 months prior to study drug\n             administration;\n\n          -  Considered unfit for the study by the Principal Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814839", 
            "org_study_id": "ALN-TTRSC-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALN-TTRSC", 
                "description": "Ascending doses of ALN-TTRSC by subcutaneous (SC) injection", 
                "intervention_name": "ALN-TTRSC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sterile Normal Saline (0.9% NaCl)", 
                "description": "Calculated volume to match active comparator", 
                "intervention_name": "Sterile Normal Saline (0.9% NaCl)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "RNAi therapeutic", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "zip": "LS2 9LH"
                    }, 
                    "name": "Clinical Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW10 7EW"
                    }, 
                    "name": "Clinical Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC in Healthy Volunteers", 
        "overall_contact": {
            "last_name": "Alnylam Clinical Trials Hotline. Call for Complete Site List.", 
            "phone": "617-575-7400 or 1-866-330-0326"
        }, 
        "overall_official": {
            "affiliation": "Alnylam Pharmaceuticals", 
            "last_name": "Jared Gollob, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs) and study drug discontinuation.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 63 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814839"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK) of ALN-TTRSC (Cmax, tmax, t1/2, AUC0-last, CL).", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Effect of ALN-TTRSC on transthyretin (TTR) (Determination of % Lowering of TTR to pretreatment/Baseline Levels).", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Effect of ALN-TTRSC on vitamin A (Determination of % Lowering of vitamin A to pretreatment/Baseline Levels).", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }, 
            {
                "measure": "Effect of ALN-TTRSC on retinol binding protein (RBP) (Determination of % Lowering of RBP to pretreatment/Baseline Levels).", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days"
            }
        ], 
        "source": "Alnylam Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alnylam Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}